Cladribine and Drospirenone, ethinyl estradiol, and levomefolate
Determining the interaction of Cladribine and Drospirenone, ethinyl estradiol, and levomefolate and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.ADDITIONAL CONTRACEPTION RECOMMENDED: Coadministration with cladribine may reduce the efficacy of hormonal contraceptives. The mechanism has not been established. There are no clinical data regarding the use of cladribine with hormonal contraceptives. MANAGEMENT: Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm. Women should avoid becoming pregnant during treatment with cladribine and for at least 6 months after the last dose in each treatment course. Women using hormonal contraceptives should add a barrier method during cladribine dosing and for at least 4 weeks after the last dose in each treatment cycle. In addition, male patients should take precautions to prevent pregnancy of their partner during cladribine dosing and for at least 6 months after the last dose in each treatment course. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ. Cerner Multum, Inc. "Australian Product Information." O 0
Professional:ADDITIONAL CONTRACEPTION RECOMMENDED: Coadministration with cladribine may reduce the efficacy of hormonal contraceptives. The mechanism has not been established. There are no clinical data regarding the use of cladribine with hormonal contraceptives.
MANAGEMENT: Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm. Women should avoid becoming pregnant during treatment with cladribine and for at least 6 months after the last dose in each treatment course. Women using hormonal contraceptives should add a barrier method during cladribine dosing and for at least 4 weeks after the last dose in each treatment cycle. In addition, male patients should take precautions to prevent pregnancy of their partner during cladribine dosing and for at least 6 months after the last dose in each treatment course.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.
- Cerner Multum, Inc. "Australian Product Information." O 0
Generic Name: cladribine
Brand name: Mavenclad, Leustatin
Synonyms: n.a.
Generic Name: drospirenone / ethinyl estradiol / levomefolate calcium
Brand name: Beyaz, Safyral, Rajani, Tydemy
Synonyms: Ethinyl Estradiol, Drospirenone, and Levomefolate
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Cladribine-DroTuss-CP
- Cladribine-Droxia
- Cladribine-Droxidopa
- Cladribine-Dry Eye Omega Benefits
- Cladribine-DryMax
- Cladribine-DryMax Syrup
- Drospirenone, ethinyl estradiol, and levomefolate-Cladribine (oral)
- Drospirenone, ethinyl estradiol, and levomefolate-Cladribine injection
- Drospirenone, ethinyl estradiol, and levomefolate-Cladribine Intravenous
- Drospirenone, ethinyl estradiol, and levomefolate-Cladribine Tablets
- Drospirenone, ethinyl estradiol, and levomefolate-Claforan
- Drospirenone, ethinyl estradiol, and levomefolate-Claforan in D5W